➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Baxter
AstraZeneca
Express Scripts
Boehringer Ingelheim
McKinsey

Last Updated: January 28, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Manidipine

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Manidipine?

Manidipine is an investigational drug.

There have been 4 clinical trials for Manidipine. The most recent clinical trial was a Phase 3 trial, which was initiated on August 20th 2015.

The most common disease conditions in clinical trials are Hypertension, Diabetes Mellitus, Type 2, and Diabetes Mellitus. The leading clinical trial sponsors are Chiesi Farmaceutici S.p.A., Mario Negri Institute for Pharmacological Research, and Korea University Guro Hospital.

There are nine hundred and twenty-seven US patents protecting this investigational drug and eight international patents.

Recent Clinical Trials for Manidipine
TitleSponsorPhase
Manidipine Versus Amlodipine in Patients With HypertensionTakeda Pharmaceuticals International, Inc.Phase 4
Manidipine Versus Amlodipine in Patients With HypertensionKorea University Guro HospitalPhase 4
Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk AssessmentServicio Gallego de SaludPhase 4

See all Manidipine clinical trials

Clinical Trial Summary for Manidipine

Top disease conditions for Manidipine
Top clinical trial sponsors for Manidipine

See all Manidipine clinical trials

US Patents for Manidipine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Manidipine   Start Trial Combination therapy Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
Manidipine   Start Trial Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)   Start Trial
Manidipine   Start Trial Ultra-pure agonists of guanylate cyclase C, method of making and using same SYNERGY PHARMACEUTICALS, INC. (New York, NY)   Start Trial
Manidipine   Start Trial Fused heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
Manidipine   Start Trial Heterocyclic compound Takeda Pharmaceutical Company Limited (Tokyo, JP)   Start Trial
Manidipine   Start Trial Treatment for diabetes in patients inappropriate for metformin therapy Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Manidipine

Drugname Country Document Number Estimated Expiration Related US Patent
Manidipine Australia AU2011249722 2030-05-05   Start Trial
Manidipine Brazil BR112012028136 2030-05-05   Start Trial
Manidipine Canada CA2797310 2030-05-05   Start Trial
Manidipine Canada CA3070513 2030-05-05   Start Trial
Manidipine Chile CL2012003053 2030-05-05   Start Trial
Manidipine China CN102946875 2030-05-05   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
AstraZeneca
Express Scripts
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.